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Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a highly lethal malignant tumor. Currently, Human
papillomavirus (HPV) is suggested as a potential risk factor for esophageal cancer (EC) in addition to the classic risk
factors, alcohol and tobacco, but this hypothesis still remains contradictory. We sought to investigate wether HPV
and well-known biomarkers (p16 and p53) and patient-related factors that may have impact on survival of ESCC.
Methods: We conducted a prospective cohort study. By using multiplex PCR, we determined the prevalence of
high risk HPV in ESCC, and evaluated the immunohistochemical expression of p16 and p53, molecular markers
related to esophageal carcinogenesis in order to verify the potential influence of these variables in patients’s
survival. Survival rates were estimated using Kaplan-Meier methods. A multivariate confirmatory model was
performed using Cox proportional hazards regression.
Results: Twelve (13.8%) of 87 patients were HPV-DNA positive. Positive reactions of p16 and p53 were 10.7% and
68.6%, respectively. Kaplan-Meier analysis indicated that men (p = 0.025) had poor specific-cancer survival and a
shorter progression-free survival (p = 0.050) as compared to women; III or IV clinical stage (p < 0.019) had poor
specific-cancer survival and a shorter progression-free survival (p < 0.001) compared to I and II clinical stage; not
submitted to surgery (<0.001) and not submitted to chemoradiotherapy (p = 0.039) had a poor specific-cancer
survival, as well. The multivariate analysis showed that HPV, p16 and p53 status are not predictive parameters of
progression-free and specific-cancer survival.
Conclusion: HPV infection and p53 and p16 expression are not prognostic factors in ESCC.
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Background
Presently, esophageal cancer (EC) is regarded as an
important public health problem worldwide, being
considered the eighth most common type of cancer
and the sixth leading cause of cancer death according
to estimates by GLOBOCAN 2012 [1].
Despite recent advances in multidisciplinary treatments,
including radical surgical resection, chemotherapy and
radiotherapy, the 5-year survival rate of patients with
esophageal squamous cell carcinoma (ESCC) remains be-
ing less than 30%, and this is due mainly to atypical early
symptoms, middle-to-late stage diagnosis, low treatment
remission rates and high local recurrence rates, requiring
the identification of a suitable biomarker to predict their
long-term survival [2, 3].
Recently, evidence suggests that human papillomavirus
(HPV) may play an important role in ESCC development;
a number of studies in this area has increased steadily, as
evidenced in several reviews [4–9]. First descriptions of
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oral lesions associated with HPV were preceded by reports
that suggested the involvement of viruses in the develop-
ment of benign [10] and malignant [11] lesions of the
squamous epithelium of the esophagus. These initial ob-
servations were based on the report of morphological
similarities between HPV lesions in the genital tract
(warts) and esophageal papillomas [10, 11].
The first report that demonstrated the presence of HPV in
ESCC occurred more than 30 years [10]; however, its preva-
lence is significantly variable among different geographical
regions, and its role in carcinogenesis is still a matter of de-
bate. Although the number of studies and interest in the sub-
ject has increased in recent years, literature is still
controversial [12]. Data accumulated reflects a trend linking
HPV infection and EC in high risk areas, whereas in low-risk
areas such association was not evident [13].
The molecular genetic background of ESCC, mainly
researches on protein alterations, has been widely
studied and may assist in the prognosis of patients [14].
Proteins such as p53, p16 and others have been consid-
ered as prognostic factors for ESCC [15].
The differential expression of the tumor suppressor pro-
tein p53 is one of the commonest abnormality in several
cancer types, including EC, and its mutation is mainly re-
lated to cell invasion and metastasis, as well as being re-
lated to advanced stages of the disease [14]. These
mutations can lead to an increase in expression of p53,
which accumulates in the nuclei and can be detected by
immunohistochemistry (IHC) methods [16, 17]. The p16
protein expression is frequently used as a surrogate
marker for HPV infection, and was shown as a marker for
responder and better prognosis among head and neck
squamous cell carcinoma patients who underwent radio-
therapy [18]. Similarly, high p16 expression supposedly
correlates with favorable prognosis in esophageal squa-
mous cell carcinoma as well [19, 20], although data are
still limited and variable [16, 18–23].
A retrospective cohort study with 136 ESCC patients has
showed that p53 overexpression was associated with poor
prognosis in these patients and a significantly independent
predictor of poor overall survival [16]. However, this prognos-
tic role of p53 overexpression in ESCC remained unclear [16].
Necessary strategies to improve prognosis and survival
rates in patients with EC require early diagnosis and
treatment, which rely on studying and exploring factors
that influence the prognosis of such neoplasia.
This study aimed to evaluate the correlation of HPV
infection and the expression of p53 and p16 with clini-
copathologic factors, and whether they are ESCC prog-
nostic factors for cancer progression (survival).
Methods
This was a prospective cohort study. Briefly, the patients
of both genders, aged above 18 years, admitted to the
Barretos Cancer Hospital, with histopathological confirm-
ation of ESCC, clinical indication for endoscopy and no
previous treatment for cancer were included. Medical re-
cords were available to obtain clinical and follow-up data.
Sample collection, HPV detection and characterization
The procedure for conducting the Digestive Endoscopy
followed the routine of the Department of Endoscopy at
Barretos Cancer Hospital using sedation, flexible video
endoscopes (Olympus 180, Japan; Fuginon 4400, Japan)
and Single-Use Radial Jaw 4 Biopsy Forceps (Boston
Scientific Corporation, Natick, MA). Biological samples
were collected from tumors tissues, fixed in 10% buff-
ered formalin and embedded in paraffin. Slides were
routinely stained with Hematoxylin-Eosin.
HPV DNA, obtainened by organic extraction [24],
was measured in all samples using type-specific PCR
bead-based multiplex genotyping (TS-MPG) assays
that combine multiplex polymerase chain reaction
(PCR) and bead based Luminex technology (Luminex
Corp., Austin, TX, USA), as described by Pastrez et
al. and da Costa et al. [25, 26].
A primer set targeting the β-globin gene were included
as a positive control for the quality of the template DNA
and the mix without sample was a negative control.
HPV multiplex PCR was performed with QIAGEN
Multiplex PCR Kit (Qiagen, Dusseldorf, Germany), ac-
cording to manufacturer’s instructions, and the details of
the reaction can be seen in Pastrez et al. [25]
methodology.
For the hybridization assay, the mean fluorescence
intensity (MFI) values were obtained when no PCR
product was added to the mixture of hybridization
was considered as background, for each probe, was
performed according to Schmitt et al. (2006) [27].
The cutoff was calculated by adding 5 MFI for 1.1 X
the value of median found, and values higher than 20
MFI was considered positive.
Immunohistochemistry
The immunohistochemistry expression of p16 and p53
proteins were analyzed in automated system (Ventana
Benchmark ULTRA, CA, USA) using a primary antibody
against p16 (monoclonal mouse anti-human p16INK4A
protein, Clone E6H4TM, ready for use, Roche Brazil)
and p53 (monoclonal mouse anti-human p53 protein,
Clone DO-7, dilution 1:1200, Cell Marque, Rocklin, CA,
USA). The scores for analysis oh the proteins and details
can be seen in a former study recently published [25].
Statistical analysis
Survival rates were estimated in months, and survival
was defined as the period from the date of diagnosis to
the date of death or the date at which information was
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last obtained from the patient. For the analysis, the event
of interest was death related to cancer to specific-cancer
survival and the locoregional recurrence, progression or
metastasis to progression-free survival. Cases that were
alive or dead from other causes were censored to
specific-cancer survival and without locoregional recur-
rence, progression or metastasis to progression-free sur-
vival. Such information was obtained through direct
consultation to the death certificate or medical records.
Multiple confirmatory models were used to check
whether HPV, p53 and p16 status were related to prog-
nosis of ESCC. Multivariable Cox proportional hazards
regression models was used to estimate hazard ratios
(HR) and 95% confidence intervals (CI) with adjustment
for sex, clinical stage and treatment. Fisher exact test
was used to association analysis. For tabulation and
statistical analysis we used IBM® SPSS® Statistics 20.0.1
software for Windows (IBM Corporation, Route 100,
Somers NY 10589). The level of statistical significance
was set at 0.05 for all analysis.
Results
During the period between February 2013 and August
2014, 123 patients with ESCC were enrolled in this
study. Age ranged from 41 to 92 years (mean = 60.9 years,
SD = 10.3 years; median = 61 years). Patients character-
istics are described in Table 1; HPV, p53 and p16 status
versus patients characteristics are depicted in Table 2.
Kaplan-Meier analysis indicated that ESCC male pa-
tients had a poor specific-cancer survival (p = 0.025) and
a shorter progression-free survival (p = 0.050); III or IV
clinical stage (p < 0.019) had a poor specific-cancer sur-
vival and a shorter progression-free survival (p < 0.001);
not submitted to surgery (<0.001) and not submitted to
chemoradiotherapy (CTR) (p = 0.039) had a poor
specific-cancer survival. Those patients with disease
progression or metastasis (<0.001) had a poor specific-
cancer survival (Table 3). The distribution of cases
according to patients’ characteristics and survival rates
are shown with more details in Table 3 and the survival
curves shown in Fig. 1.
In the multivariate analysis, using a confirmatory
model, HPV, p16 and p53 did not show any prediction
value related to the progression-free and specific-cancer
survival. Results of the multivariable Cox regression ana-
lysis are shown in Table 4.
Discussion
Esophageal cancer is an extremely aggressive disease,
which is usually diagnosed at an advanced stage, due
mainly to the lack of specific initial symptoms.
Consequently, EC infiltrates organs and metastasizes
straightforwardly, resulting in poor prognosis and 5-
year survival of 15–34% [28–30]. In cases of advanced
disease, it is well established that standard treatment
is CRT followed by surgery [31], which leads to
downgrade the tumor stage and increase the
complete resection rate [2]. However, the cure rate
and survival of these patients is still low, requiring
other methods which may assist in predicting sur-
vival and identification of potential responders to a
given therapy.
Until now, published data demonstrate that clinic-
histopathological factors, molecular biomarkers, and
HPV infection are, possibly, predictive variables for
neoadjuvant therapy [2, 31]. In head and neck cancer,
HPV-positive patients have a better response to CRT
Table 1 Patients’ characteristics
Variable Category
n %
Sex Female 23 18.7
Male 100 81.3
Age at diagnosis ≤ 60 years old 60 48.8
> 60 years old 63 51.2
Alcohol consumption ≤ 20 years 24 19.5
>20 years 99 80.5
Tobacco consumption ≤20 years 26 21.1
>20 years 97 78.9
Clinical stagea I 3 2.6
II 26 22.8
III 58 50.9
IV 27 23.7
Histological grade * Well differentiated 14 11.6
Moderately differentiated 73 60.3
Poorly differentiated 34 28.1
Surgery No 102 82.9
Yes 21 17.1
Radiotherapy No 51 41.5
Yes 72 58.5
Chemotherapy No 45 36.6
Yes 78 63.4
Progression No 84 68.3
Yes 39 31.7
Status Death by cancer 93 75.6
Alive 30 24.4
HPVa Negative 75 86.2
Positive 12 13.8
p16a Negative 108 89.3
Positive 13 10.7
p53a Negative 37 31.4
Positive 81 68.6
aThere are missing values
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and a higher survival rate in relation to HPV-negative
cancers [32–34]. Due to the fact that the esophagus
can also be infected with these viruses, a similar asso-
ciation and clinical characteristics [20] are supposed.
However, the impact of HPV infection on the progno-
sis of ESCC is still uncertain [2, 35]. In addition, the
recent advances in HPV vaccination can believed to
improve the reduction of HPV-related tumors in non-
gynecological cancers, which is a optimistic scenario
to be proved in near future [36].
Previous work of our study group showed a rate of
high-risk HPV infection in esophageal tumor samples
(13.8%) [25, 26], which led us to investigate whether this
event could influence the survival of our patients.
Table 2 HPV, p53 and p16 status versus patients’ characteristics
Treatment HPVa p p16a p p53a p
Negative Positive Negative Positive Negative Positive
Sex
Female 16 (21.3) 3 (25.0) 0.720 18 (16.7) 5 (38.5) 0.071 6 (16.2) 17 (21.0) 0.624
Male 59 (78.7) 9 (75.0) 90 (83.3) 8 (61.5) 31 (83.8) 64 (79.0)
Age at diagnosis
≤ 60 years old 39 (52.0) 7 (58.3) 0.763 51 (47.2) 7 (53.8) 0.772 14 (37.8) 44 (54.3) 0.115
> 60 years old 36 (48.0) 5 (41.7) 57 (52.8) 6 (46.2) 23 (62.2) 37 (45.7)
Alcohol consumption
≤ 20 years 19 (25.3) 2 (16.7) 0.722 21 (19.4) 3 (23.1) 0.720 7 (18.9) 17 (21.0) 0.813
> 20 years 56 (74.7) 10 (83.3) 87 (80.6) 10 (76.9) 30 (81.1) 64 (79.0)
Tobacco consumption
≤ 20 years 14 (18.7) 5 (41.7) 0.125 25 (23.1) 1 (7.7) 0.295 8 (21.6) 18 (22.2) 0.572
> 20 years 61 (81.3) 7 (58.3) 83 (76.9) 12 (92.3) 29 (78.4) 63 (77.8)
Clinical stage
I or II 21 (29.2) 2 (16.7) 0.497 26 (26.0) 3 (23.1) 1.000 5 (14.3) 23 (30.3) 0.099
III or IV 51 (70.8) 10 (83.3) 74 (74.0) 10 (76.9) 30 (85.7) 53 (69.7)
Histological grade
Well differentiated 11 (15.1) 0 (0.0) 0.442 13 (12.3) 1 (7.7) 0.912 7 (18.9) 7 (8.9) 0.264
Moderately differentiated 42 (57.5) 9 (75.0) 62 (58.5) 9 (69.2) 19 (51.4) 49 (62.0)
Poorly differentiated 20 (27.4) 3 (25.0) 31 (29.2) 3 (23.1) 11 (29.7) 23 (29.1)
Surgery
No 58 (77.3) 12 (100.0) 0.112 95 (88.0) 7 (53.8) 0.006 31 (83.8) 69 (85.2) 1.000
Yes 17 (22.7) 0 (0.0) 13 (12.0) 6 (46.2) 6 (16.2) 12 (14.8)
Chemoradiotherapy
No 18 (24.0) 0 (0.0) 0.140 24 (22.2) 2 (15.4) 0.803 7 (18.9) 17 (21.0) 0.871
Chemo or Radio 25 (33.3) 6 (50.0) 38 (35.2) 4 (30.8) 12 (32.4) 29 (35.8)
Chemo and Radio 32 (42.7) 6 (50.0) 46 (42.6) 7 (53.8) 18 (48.6) 35 (43.2)
HPV
Negative – – – 65 (85.5) 9 (90.0) 1.000 24 (88.9) 47 (83.9) 0.743
Positive – – 11 (14.5) 1 (10.0) 3 (11.1) 9 (16.1)
p16a
Negative 65 (87.8) 11 (91.7) 1.000 – – – 34 (91.9) 72 (88.9) 0.751
Positive 9 (12.2) 1 (8.3) – – 3 (8.1) 9 (11.1)
p53a
Negative 24 (33.8) 3 (25.0) 0.743 34 (91.9) 72 (88.9) 0.751 – – –
Positive 47 (66.2) 9 (75.0) 3 (8.1) 9 (11.1) – –
aThere are missing values
Entries in boldface are significantly different
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However, the current study demonstrated that HPV in-
fection showed no impact on the survival of patients
with ESCC and similar results were found in other
studies [2, 35, 37, 38].
Hippelainen et al. (1993), e.g., detected HPV in 11% of
the esophageal tumors analyzed but the infection was
not associated with higher survival rate [38]. Dreilich et
al. (2006) detected only HPV 16 in their esophageal sam-
ples and showed no influence of virus in survival or im-
provement of therapy response [35]. Liu et al. (2010)
demonstrated that infection of HPV 16 and p53 protein
expression were not correlated with survival during the
5-year follow-up period in ESCC [37]. Herbster et al.
(2012) found mostly HPV 16 positive in esophageal
Table 3 Survival rates according to clinical and pathological data
Variable Progression-free survival Specific survival
Total events One-year p-value Total events One-year p-value
Sex
Female 4 86.7 0.050 14 72.3 0.025
Male 35 63.3 79 49.8
Age at diagnosis
≤ 60 years old 18 73.3 0.553 45 54.9 0.266
> 60 years old 21 63.0 48 53.2
Alcohol consumption
≤ 20 years 5 74.6 0.218 16 62.0 0.301
> 20 years 34 66.9 77 52.0
Tobacco consumption
≤ 20 years 11 51.3 0.158 19 49.0 0.796
> 20 years 28 73.1 74 55.3
Clinical stagea
I or II 6 91.2 0.019 13 78.6 <0.001
III or IV 32 57.9 73 44.2
Histological gradea
Well differentiated 4 76.2 0.170 10 63.5 0.426
Moderately differentiated 18 72.4 55 48.8
Poorly differentiated 15 57.4 26 61.4
Surgery
No 32 65.8 0.486 84 47.5 <0.001
Yes 7 80.0 9 85.4
Chemoradiotherapy
No 8 72.4 0.731 24 34.6 0.039
Chemo or Radio 15 62.3 36 47.7
Chemo and Radio 16 72.9 33 69.1
HPVa
Negative 23 69.3 0.885 56 52.6 0.093
Positive 3 71.4 11 31.3
p16a
Negative 35 66.9 0.956 84 52.4 0.739
Positive 4 75.2 9 60.6
p53a
Negative 12 66.3 0.892 27 51.4 0.584
Positive 26 67.0 63 54.9
aThere are missing values
Entries in boldface are significantly different
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tumors, but this condition was not associated with
overall survival [39]. Recently, Wang et al. (2015) dem-
onstrated that the risk of developing multifocal ESCC
was not significantly different between HPV-positive and
HPV-negative groups. However, patients with HPV16 in-
fection, specifically, had better response to CRT than
those without HPV 16 infection [2].
Different results have also been reported in other stud-
ies. Cao et al. (2014) demonstrated that HPV infected
patients had better 5-year rates of overall survival and
reduction in the risk of death [22]. In contrast, Furihata
et al. (1993) reported that HPV positive patients have
worse survival than those HPV negative with overex-
pression of p53 in EC patients [40].
In addition to investigating HPV infection in EC,
our group has also previously assessed the expression
of molecular markers p53 and p16, considered to be
essential G1 cell cycle regulatory genes whose loss of
function is associated with ESCC carcinogenesis [41],
and found that the expression of these proteins was
significantly higher in tumor tissues compared to ad-
jacent normal tissue to the tumor and also esophageal
tissue from individuals without EC [25]. Based on this
interesting result, we decided to evaluate the impact
of increased expression of these proteins in EC as
regards the survival of these patients. We find,
through a multivariate analysis, that p53 and p16 ex-
pression showed no predictive value for progression-
free and specific-cancer survival. The results found in
literature related to the expression of these markers
and survival in ESCC are widely variable.
Currently, there are several studies trying to correlate
the expression of p53 protein and mutations in the p53
gene with survival of patients carrying EC, and the
results are widely variable. Bahnassy et al. (2005) and
Huang et al. (2014) found that high p53 expression was
associated with a poor survival rate in ESCC patients
[42, 43]; and Han et al. (2007) showed that p53 expres-
sion was positively correlated with tumor stage and
lymph node metastasis [44]. Ye et al. (2012) reported
that p53 expression was not associated with the gender
or age of the patient, but was associated with tumor
differentiation degree and lymph node metastasis [45]. A
retrospective cohort study of 136 ESCC patients,
conducted to investigate the prognostic role of p53 in
patients with ESCC suggested that overexpression of this
protein was associated with poor prognosis in these
patients, and it’s a significantly independent predictor of
poorer overall survival (p = 0.04) [16]. Furthermore,
significant associations were also found between high
expression of p53 and poor prognosis by Shang et al.
(2014), Xu et al. (2014) and Chen et al. (2015), suggest-
ing that this protein is an important biomarker candi-
date for the prognosis of patients with ESCC [3, 14, 23].
Similarly to our results, Chino et al. (2001) showed
that p53 expression was not associated with tumor
infiltration deepness, lymph node metastasis, or ven-
ous and/or lymphatic invasion [46]. Murata et al.
(2013) examined the clinical and prognostic features
of p53 immunohistochemical expression in 266 ESCC
patients and found that the protein expression has no
impact on the prognosis of ESCC, according to them,
possibly due to their short follow-up time [47].
Furthermore, a p53 research group study demon-
strated that, for EC, p53 immunohistochemistry does
not correlate with response to chemotherapy, curative
a b c
Fig. 1 Kaplan Meier curves for specific-cancer survival according HPV, p53 and p16 status
Table 4 Risk of cancer progression or death according to HPV,
p53 and p16 status
Model Variable
of interesta
Progression-free survival Specific-cancer survival
HR [CI95%] HR [CI95%]
1 HPV 1.042 [0.293: 3.709] 1.901 [0.926: 3.900]
2 p16 1.137 [0.383: 3.378] 1.268 [0.617: 2.604]
3 p53 1.318 [0.646: 2.689] 1.177 [0.726: 1.907]
aModel adjusted by sex. Clinical stage and treatment (surgery and
chemoradiotherapy). HR: Hazard ratio
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resection rate, or prognosis, whereas data from p53
mutation analyses are more consistent concerning the
association of p53 mutation and poor survival [48].
These discrepancies may be related to several factors,
including small sample sizes, patient selection bias,
failure to take into account other prognostic parame-
ters, differences in laboratory techniques (for example, the
use of different monoclonal antibodies to screen for p53
expression) and a shorter time of follow-up [16, 47]. To
date, the role of this protein in relation to EC patients’ sur-
vival is not fully understood.
Unlike the large number of findings related to p53
overexpression and survival, studies seeking to correlate
p16 expression with EC patient survival are scarce, since
the vast majority uses this protein as an indirect marker
for HPV infection.
Opposite to our findings, Cao et al. (2014) found
that p16-positive patients had better 5-year rates of
overall survival and progression free survival than
p16-negative group [22] and similarly, Kumar et al.
(2015) found that the p16 expression in ESCC
correlates with a higher rate of pathologic complete
remission in patients submitted to neo adjuvant
chemotherapy, and could be considered as a predict-
ive marker for response assessment. Furthermore,
moderately differentiated histological grade, surgery,
chemotherapy and progression or metastasis have
shown their prediction value for specific-cancer sur-
vival [21]. However, no significant correlations were
found between the proteins expression and clinical
outcomes[1515], corroborating our findings.
Conclusions
HPV status did not statistically correlated to survival
rates, despite the clear tendency of positive HPV cases to
be more aggressive than the HPV negative, in opposition
to HPV significance in oropharyngeal cancers.
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